Literature DB >> 8954059

Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia.

K Ozono1, M Yamagata, T Michigami, S Nakajima, N Sakai, G Cai, K Satomura, N Yasui, S Okada, M Nakayama.   

Abstract

Hypophosphatasia is associated with a defect of the tissue-non-specific alkaline phosphatase gene. We performed a mutational analysis in a surviving patient diagnosed at birth as having hypophosphatasia, on the basis of a low level of serum alkaline phosphatase (ALP) activity and characteristic radiographical findings. She had two sisters, one of whom died of respiratory failure complicated by perinatal hypophosphatasia; the other seemed healthy, with a relatively low activity level of ALP. The patient's parents also had low ALP activity. Sequence analysis of the tissue-nonspecific alkaline phosphatase gene was performed, using genomic DNA and total RNA from the skin fibroblasts of the patient and the peripheral mononuclear cells of her parents. The conversion of Phe to Leu at codon 310 (F310L) and Gly to Arg at 439 (G439R) were identified in the patient. Interestingly, the reconstructive experiments demonstrated that the F310L mutant exhibited an ALP activity level 65% of the normal level, whereas the mutant G439R had no activity. Moreover, the digestion by StuI, after a PCR using complementary DNA extracted from fibroblasts of the patient and lymphocytes of her father, revealed a relatively low messenger RNA level of F310L. These findings suggest that the neonatal case of hypophosphatasia was associated with compound mutations, one of which caused the loss of ALP activity and the other of which caused a slight reduction of the ALP activity, with a relatively low level of messenger RNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8954059     DOI: 10.1210/jcem.81.12.8954059

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Possible interference between tissue-non-specific alkaline phosphatase with an Arg54-->Cys substitution and acounterpart with an Asp277-->Ala substitution found in a compound heterozygote associated with severe hypophosphatasia.

Authors:  M Fukushi-Irié; M Ito; Y Amaya; N Amizuka; H Ozawa; S Omura; Y Ikehara; K Oda
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Adult hypophosphatasia with painful periarticular calcification treated with surgical resection.

Authors:  Kei-Ichiro Iida; Jun-Ichi Fukushi; Toshifumi Fujiwara; Yoshinao Oda; Yukihide Iwamoto
Journal:  J Bone Miner Metab       Date:  2011-12-15       Impact factor: 2.626

3.  Hypophosphatasia - pathophysiology and treatment.

Authors:  José Luis Millán; Horacio Plotkin
Journal:  Actual osteol       Date:  2012-09-01

4.  Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia.

Authors:  Toshimi Michigami; Takayuki Uchihashi; Akira Suzuki; Kanako Tachikawa; Shigeo Nakajima; Keiichi Ozono
Journal:  Eur J Pediatr       Date:  2005-01-20       Impact factor: 3.183

5.  Glu274Lys/Gly309Arg mutation of the tissue-nonspecific alkaline phosphatase gene in neonatal hypophosphatasia associated with convulsions.

Authors:  O Reish; T Dolfin; S Arnon; R Regev; G Grinshpan; M Yamazaki; K Ozono
Journal:  J Inherit Metab Dis       Date:  2002-02       Impact factor: 4.982

Review 6.  Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.

Authors:  Michael P Whyte
Journal:  Nat Rev Endocrinol       Date:  2016-02-19       Impact factor: 43.330

7.  Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals.

Authors:  H C Anderson; H H Hsu; D C Morris; K N Fedde; M P Whyte
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

8.  Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.

Authors:  Michael P Whyte; Cheryl Rockman-Greenberg; Keiichi Ozono; Richard Riese; Scott Moseley; Agustin Melian; David D Thompson; Nicholas Bishop; Christine Hofmann
Journal:  J Clin Endocrinol Metab       Date:  2015-11-03       Impact factor: 5.958

9.  Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth.

Authors:  Yoko Okazaki; Hiroyuki Kitajima; Narutaka Mochizuki; Taichi Kitaoka; Toshimi Michigami; Keiichi Ozono
Journal:  Eur J Pediatr       Date:  2015-10-12       Impact factor: 3.183

10.  Autosomal recessive hypophosphatasia manifesting in utero with long bone deformity but showing spontaneous postnatal improvement.

Authors:  David A Stevenson; John C Carey; Stephen P Coburn; Karen L Ericson; Janice L B Byrne; Steven Mumm; Michael P Whyte
Journal:  J Clin Endocrinol Metab       Date:  2008-06-17       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.